HTG2014-Section-Header-publications

Publications

Explore HTG publications
with our new search tool. Launch Now

Categories

Reset Categories

Filter by Topics

AACR2023 ADCC Gene Alteration adolescents ALK Angiogenesis Apoptosis Autocrine Signaling B-accute lyphoblastic seukemia B-ALL Biology of neoplasia Biomarkers Bladder Cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN Blood bone Brain Breast Cancer CAR T cell therapy Cardiovascular Disease CDKN2A mutation Cell Free Plasma Cells Chemokines Circulating miRNAs clinical trial Colorectal cancer Comparison study Core Needle Biopsy COVID-19 Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug sensitivity Efficacy EHE cancer EMT Epstein-Barr ERBB3 Esophageal Cancer estrogen and progesteron receptors Exosomes extracellular miRNAs Extracellular Vesicles Feasibility FFPE FGF Ligand Trap FGFR Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER-2 HER2- HLA-E Homing HPV HR+ HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Cells Immune Checkpoint Inhibitors Immune Response Immune System Immuno-Oncology Immunotherapy Integrins IOA- 244 IRP Kidney LAG3+ Liposarcoma Liquid Biopsy liver Liver liver tissue Lung lungs Lupus Lymphocytes Lymphoma lymphoma Melanoma melanoma Mesothelioma Microenvironment miRNA miRNA WTA Molecular Characterization Mouse mRNA custom mTOR signaling Multiple Myeloma MYC Natural Killer Cells Neoantigens Novel Therapeutic Targets OBP Oral Cancer Oral cancer oral squamous cell carcinoma OSCC Osteoarthritis palbociclib PALLET PALOMA PALOMA-2 PanB Pancreas Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-L1 PDX model PENELOPE-B PFAS PI3K inhibitors PIK3CA mutation PIP Plasma Platform Comparison Programmed cell death protein 1 Prostate Prostate Cancer qNPA qPCR Rbsig Renal Cell Carcinoma Reproductive Reveal Rheumatoid Arthritis safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Squamous cell carcinoma STAT6 pathway Sub-typing Testicular cancer Therapeutic Response TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Triple Negative Breast CancerTNBC Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Microenvironment tumor microenvironment Urine Urothelial carcinoma VEGFR Xenograft Tissue
Reset Filter Reset All

2021

Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel.

Jaramillo, M. C., et al. Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel. J Clin Oncol 39, 2021 (suppl 15; abstr e14528). DOI: 10.1200/JCO.2021.39.15_suppl.e14528

View External Link

2020

Tumor Microenvironment Associated with complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action

Song, Y., et al. Tumor Microenvironment Associated with complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. Blood Journal 2020. NOV 5 136(S1):10-11.

View External Link

77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)

Hou, M. M., et al. 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC). Journal for Immunotherapy of Cancer 2020(8)S3. Pre-print

Download pdf 946KB

78 T-Cell, MHC I, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma

Ye, D., et al. 78 T-Cell, MHC I, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. Journal for Immunotherapy of Cancer 2020(8)S3: A1-A959- pre-print

Download pdf 1.0MB

Comparative Transcriptomics of Prostate Tumor Show Enrichment of Biologically Distinct Pathways Among Men of African Origin

Yamoah, K., et al. Comparative Transcriptomics of Prostate Tumor Show Enrichment of Biologically Distinct Pathways Among Men of African Origin. International Journal of Radiation Oncology, Biology, Physics. Oral Scientific Session 2020 NOV 1 (108)3;S48

Download pdf 188KB

Extraction-Free Comprehensive Transcriptome Sequencing of Carcinoma in Situ Is Highly Feasible and Insightful in Non-Muscle Invasive Bladder Cancer

Hahn, N., et al. Extraction-Free Comprehensive Transcriptome Sequencing of Carcinoma in Situ Is Highly Feasible and Insightful in Non-Muscle Invasive Bladder Cancer. Abstract presented at IBCN 2020 Virtual Meeting: 2020 OCT 17. UroToday Conference Highlights.

View External Link

Analysis of the microenvironment of follicular lymphoma by gene expression analysis: importance of the Th17 axis

Menter, T., et al. Analysis of the microenvironment of follicular lymphoma by gene expression analysis: importance of the Th17 axis. Abstract presented at the 104th Annual Meeting of the German Society for Pathology 2020 Jun 4-6; Virtual Conference

Download pdf 2.2MB
View External Link

Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma

Xu, J., et al. Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma. J Clin Oncol 38: 2020 (suppl; abstr 3115). 

Download jpg 6.4MB
View External Link

Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC).

Desai, J., et al. Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC). J Clin Oncol 38: 2020 (suppl; abstr e15258). 

View External Link

Page last updated May 22, 2023